|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3322-3330.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEW
Bcl-2–family proteins and hematologic malignancies: history and future prospects
John C. Reed1
1 Burnham Institute for Medical Research, La Jolla, CA
BCL-2 was the first antideath gene dis-covered, a milestone that effectively launched a new era in cell death research. Since its discovery more than 2 decades ago, multiple members of the human Bcl-2 family of apoptosis-regulating proteins have been identified, including 6 antiapoptotic proteins, 3 structurally similar proapoptotic proteins, and several structurally diverse proapoptotic interacting proteins that operate as upstream agonists or antagonists. Bcl-2–family proteins regulate all major types of cell death, including apoptosis, necrosis, and autophagy. As such, they operate as nodal points at the convergence of multiple pathways with broad relevance to biology and medicine. Bcl-2 derives its name from its original discovery in the context of B-cell lymphomas, where chromosomal translocations commonly activate the BCL-2 protooncogene, endowing B cells with a selective survival advantage that promotes their neoplastic expansion. The concept that defective programmed cell death contributes to malignancy was established by studies of Bcl-2, representing a major step forward in current understanding of tumorigenesis. Experimental therapies targeting Bcl-2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anticancer drugs may be near.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Blood,
May 28, 2009;
113(22):
5549 - 5557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kang and C. P. Reynolds
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Clin. Cancer Res.,
February 15, 2009;
15(4):
1126 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Deng, F. Gao, and W. S. May
Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding
Blood,
January 8, 2009;
113(2):
422 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. G.E. de Vries and S. de Jong
Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run
J. Clin. Oncol.,
November 10, 2008;
26(32):
5151 - 5153.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Tan, M. Husain, C. M. Manlandro, M. Koppenol, A. Z. Fire, and R. B. Hill
CED-9 and mitochondrial homeostasis in C. elegans muscle
J. Cell Sci.,
October 15, 2008;
121(20):
3373 - 3382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
